HC Wainwright Begins Coverage on Predictive Oncology (NASDAQ:POAI)

HC Wainwright assumed coverage on shares of Predictive Oncology (NASDAQ:POAI) in a research report report published on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $3.00 price target on the medical instruments supplier’s stock. HC Wainwright also issued estimates for Predictive Oncology’s Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.05 EPS, FY2025 earnings at ($0.16) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.43 EPS.

Predictive Oncology Price Performance

Shares of Predictive Oncology stock opened at $0.97 on Monday. The firm has a market cap of $3.98 million, a price-to-earnings ratio of -0.27 and a beta of 1.15. Predictive Oncology has a 52-week low of $0.85 and a 52-week high of $4.70. The stock has a 50-day simple moving average of $1.07 and a 200-day simple moving average of $1.80.

Institutional Investors Weigh In On Predictive Oncology

A hedge fund recently bought a new stake in Predictive Oncology stock. Carnegie Mellon University purchased a new stake in shares of Predictive Oncology Inc. (NASDAQ:POAI) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology comprises approximately 0.0% of Carnegie Mellon University’s holdings, making the stock its 5th biggest position. Carnegie Mellon University owned approximately 0.26% of Predictive Oncology as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 9.04% of the company’s stock.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.